Lest we forget the endothelial glycocalyx in sepsis

Critical Care

Volumn 16, Issue 2, 2012, Pages

  Burke Gaffney, Anne ^a   Evans, Timothy W ^a,b  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; GLYCOSAMINOGLYCAN; PROTEOGLYCAN; STEROID; BIOLOGICAL MARKER;

DISEASE MARKER; ENDOTHELIAL DYSFUNCTION; GLYCOCALYX; HUMAN; IMMUNE RESPONSE; NOTE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN STRUCTURE; SEPSIS; METABOLISM; MULTIPLE ORGAN FAILURE; PATHOLOGY; VASCULAR ENDOTHELIUM;

BIOMARKERS; ENDOTHELIUM, VASCULAR; GLYCOCALYX; HUMANS; MULTIPLE ORGAN FAILURE; SEPSIS;

EID: 84859270435     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc11239     Document Type: Note

References (15)

1. Xing K, Murthy S, Liles WC, Singh JM. Clinical utility of biomarkers of endothelial activation in sepsis - a systematic review. Crit Care 2012, 16:R7. 10.1186/cc11145, 22248019.
2. Paulus P, Jennewein C, Zacharowski K. Biomarkers of endothelial dysfunction: can they help us deciphering systemic inflammation and sepsis?. Biomarkers 2011, 16(Suppl 1):S11-S21.
3. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care 2010, 14:R15. 10.1186/cc8872, 2875530, 20144219.
4. Van Teeffelen JW, Brands J, Stroes ES, Vink H. Endothelial glycocalyx: sweet shield of blood vessels. Trends Cardiovasc Med 2007, 17:101-105. 10.1016/j.tcm.2007.02.002, 17418372.
5. Choi Y, Chung H, Jung H, Couchman JR, Oh ES. Syndecans as cell surface receptors: unique structure equates with functional diversity. Matrix Biol 2011, 30:93-99. 10.1016/j.matbio.2010.10.006, 21062643.
6. Nieuwdorp M, Meuwese MC, Vink H, Hoekstra JB, Kastelein JJ, Stroes ES. The endothelial glycocalyx: a potential barrier between health and vascular disease. Curr Opin Lipidol 2005, 16:507-511. 10.1097/01.mol.0000181325.08926.9c, 16148534.
7. Broekhuizen LN, Mooij HL, Kastelein JJ, Stroes ES, Vink H, Nieuwdorp M. Endothelial glycocalyx as potential diagnostic and therapeutic target in cardiovascular disease. Curr Opin Lipidol 2009, 20:57-62. 10.1097/MOL.0b013e328321b587, 19106708.
8. Chappell D, Westphal M, Jacob M. The impact of the glycocalyx on microcirculatory oxygen distribution in critical illness. Curr Opin Anaesthesiol 2009, 22:155-162. 10.1097/ACO.0b013e328328d1b6, 19307890.
9. Manon-Jensen T, Itoh Y, Couchman JR. Proteoglycans in health and disease: the multiple roles of syndecan shedding. FEBS J 2010, 277:3876-3889. 10.1111/j.1742-4658.2010.07798.x, 20840585.
10. Nelson A, Berkestedt I, Schmidtchen A, Ljunggren L, Bodelsson M. Increased levels of glycosaminoglycans during septic shock: relation to mortality and the antibacterial actions of plasma. Shock 2008, 30:623-627. 10.1097/SHK.0b013e3181777da3, 18497712.
11. Sallisalmi M, Tenhunen J, Yang R, Oksala N, Pettila V. Vascular adhesion protein-1 and syndecan-1 in septic shock. Acta Anaesthesiol Scand 2012, 56:316-322. 10.1111/j.1399-6576.2011.02578.x, 22150439.
12. Steppan J, Hofer S, Funke B, Brenner T, Henrich M, Martin E, Weitz J, Hofmann U, Weigand MA. Sepsis and major abdominal surgery lead to flaking of the endothelial glycocalyx. J Surg Res 2011, 165:136-141. 10.1016/j.jss.2009.04.034, 19560161.
13. Kohler M, Kaufmann I, Briegel J, Jacob M, Goeschl J, Rachninger W, Thiel M, Rehm M. The endothelial glycocalyx degenerates with increasing sepsis severity. Crit Care 2011, 15(Suppl 3):P22.
14. Angus DC. The search for effective therapy for sepsis: back to the drawing board?. JAMA 2011, 306:2614-2615. 10.1001/jama.2011.1853, 22187284.
15. Becker BF, Chappell D, Bruegger D, Annecke T, Jacob M. Therapeutic strategies targeting the endothelial glycocalyx: acute deficits, but great potential. Cardiovasc Res 2010, 87:300-310. 10.1093/cvr/cvq137, 20462866.